SME3110 (Fluvoxamine Maleate) in the Treatment of Depression/Depressive State : A Post-Marketing Clinical Study in Children and Adolescents (8 Through 18 Years of Age) -A Double-Blind, Randomized, Placebo-Controlled Study.

Trial Profile

SME3110 (Fluvoxamine Maleate) in the Treatment of Depression/Depressive State : A Post-Marketing Clinical Study in Children and Adolescents (8 Through 18 Years of Age) -A Double-Blind, Randomized, Placebo-Controlled Study.

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Apr 2010

At a glance

  • Drugs Fluvoxamine (Primary)
  • Indications Depressive disorders
  • Focus Therapeutic Use
  • Sponsors Solvay Pharmaceuticals
  • Most Recent Events

    • 14 Jul 2009 Actual patient number (90) added as reported by ClinicalTrials.gov.
    • 14 Jul 2009 Actual initiation date changed from Jun 2006 to Oct 2006 as reported by ClinicalTrials.gov.
    • 14 Jul 2009 Actual end date (Jul 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top